Cipla enters into partnership with Premier Medical Corporation

16 Dec 2020 Evaluate

Cipla has entered into partnership with the Premier Medical Corporation for commercialization of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.

This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1311.75 -14.10 (-1.06%)
02-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1628.90
Dr. Reddys Lab 1182.35
Cipla 1311.75
Zydus Lifesciences 879.25
Lupin 2128.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×